Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

Journal of Clinical Oncology

Volumn 28, Issue 11, 2010, Pages 1850-1855

  Bellmunt, Joaquim ^a   Choueiri, Toni K ^a   Fougeray, Ronan ^a   Schutz, Fabio A B ^a   Salhi, Yacine ^a   Winquist, Eric ^a   Culine, Stéphane ^a   Von Der Maase, Hans ^a   Vaughn, David J ^a   Rosenberg, Jonathan E ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PLATINUM; VINFLUNINE; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LABORATORY TEST; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA; BLADDER TUMOR; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 77951626194     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.4599     Document Type: Article

References (20)

1. Bellmunt J, Albiol S, Suarez C, et al: Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 69:211-222, 2009
2. Geller NL, Sternberg CN, Penenberg D, et al: Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 67:1525-1531, 1991
3. Bajorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999 (Pubitemid 29470648)
4. von der Maase H, Sengelov L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608, 2005 (Pubitemid 46224062)
5. Lin CC, Hsu CH, Huang CY, et al: Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens. Urology 69:479-484, 2007
6. Stadler WM, Hayden A, von der Maase H, et al: Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 7:153-157, 2002
7. Bellmunt J, Albanell J, Paz-Ares L, et al: Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95:751-757, 2002 (Pubitemid 34839666)
8. Sengeløv L, Nielsen OS, Kamby C, et al: Platinum analogue combination chemotherapy: Cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors - A phase II trial with evaluation of prognostic factors. Cancer 76:1797-1803, 1995
9. Jessen C, Agerbaek M, Von Der Maase H: Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy. Acta Oncol 48:411-417, 2009
10. Bellmunt J, Theodore C, Demkov T, et al: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461, 2009
11. Chen CH, George SL: The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. Stat Med 4:39-46, 1985 (Pubitemid 15142525)
12. Vaughn DJ, Srinivas S, Stadler WM, et al: Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study. Cancer 115:4110-4117, 2009
13. Raghunathan TE, Lepkowski JM, Van Hoewyk J, et al: A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv Methodol 27:85-95, 2001
14. Rubin DB: Multiple Imputation for Nonresponse in Surveys. New York, NY, John Wiley & Sons, 1987
15. Culine S, Theodore C, De Santis M, et al: A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94:1395-1401, 2006 (Pubitemid 43772272)
16. Lorusso V, Pollera CF, Antimi M, et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum: Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34:1208-1212, 1998 (Pubitemid 28342111)
17. McCaffrey JA, Hilton S, Mazumdar M, et al: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15:1853-1857, 1997
18. Sternberg CN, Calabro F, Pizzocaro G, et al: Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92:2993-2998, 2001 (Pubitemid 33136193)
19. Sweeney CJ, Roth BJ, Kabbinavar FF, et al: Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24:3451-3457, 2006 (Pubitemid 46638903)
20. Witte RS, Elson P, Bono B, et al: Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15:589-593, 1997 (Pubitemid 27074226)